Company Overview and News

 
Knowing Futures and Options-I

2018-07-19 freepressjournal.in
Futures and Options (F&O) is a relatively late entrant to the Indian market. Prior to that, speculative transactions used to be carried out under a system called ‘Badla’ – the Badla system was inefficient in as much as fraudsters could easily manipulate it to defraud and cheat investors. F&O is a refined, more efficient medium of speculation. Since the subject matter is complex, we intend to carry it over three parts.
OPTI

 
Knowing Futures and Options-I

2018-07-16 freepressjournal.in
Futures and Options (F&O) is a relatively late entrant to the Indian market. Prior to that, speculative transactions used to be carried out under a system called ‘Badla’ – the Badla system was inefficient in as much as fraudsters could easily manipulate it to defraud and cheat investors. F&O is a refined, more efficient medium of speculation. Since the subject matter is complex, we intend to carry it over three parts.
OPTI

 
Canadian Metals Inc. Appointments Patsie Ducharme Senior Vice President Finance and Chief Financial Officer

2018-06-28 globenewswire
MONTREAL, June 28, 2018 (GLOBE NEWSWIRE) -- Canadian Metals Inc. (The “Corporation”) (CSE:CME) is pleased to announce the appointment of Patsie Ducharme CPA as Senior Vice President Finance & Chief Financial Officer to replace Pierre Monet effective July 1, 2018.
TMBCF OPTI

 
Bank Nifty Calls see uptick in demand

2018-06-20 thehindubusinessline
Bank Nifty index declined on Tuesday taking cues from weak Asian and European markets. Bank Nifty Futures June contract was down by 125.45 points to end at 2,6260.80. The contract is trading at a 5-point discount to its underlying Bank Nifty index.
OPTI

 
Subdued trade movement seen in Bank Nifty calls

2018-06-07 thehindubusinessline
The Bank Nifty index ended higher on Wednesday shrugging off the rate hike by the RBI. The markets have discounted the rate hike, it seems. The Bank Nifty Futures June contract was up by 125 points on Wednesday and closed at 26383 levels. The contract is trading at a premium of 16 points to its underlying Bank Nifty index.
OPTI

 
Open interest seen cutting across bank Nifty put options

2018-05-30 thehindubusinessline
The Bank Nifty Futures May contract fell by 374 points on Tuesday and closed at 26,167 levels. The contract is trading at a discount to its underlying Bank Nifty index, which fell about 359 points to close at 26,254. The sectoral indices related to Bank Nifty also showed a negative trend. The Nifty PSU Bank index fell 89 points or 2.95 per cent to end at 2,940 levels, while the Nifty PVT Bank index also slipped 200 points or 1.
FORTIS 532843 OPTI

239
Pay-to-Use Facebook, Inc.? The Option’s Likely Coming, But…

2018-04-11 investorplace
As expected, the Congressional grilling of Facebook, Inc. (NASDAQ:FB) CEO Mark Zuckerberg was quite the spectacle. And, given the 4.5% rebound FB stock dished out following Tuesday’s meeting, investors clearly felt Zuck won whatever game was being played in Washington, D.C.
FB AMZN TWTR NFLX SNAP OPTI

28
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2018-03-21 globenewswire
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV MS BR OPTI

 
CordovaCann Signs Exclusive Option to Enter California Cannabis Market

2018-03-13 accesswire
TORONTO, ON / ACCESSWIRE / March 13, 2018 / CordovaCann Corp. (OTCQB: LVRLF) ("CordovaCann" or the "Company") announced today that the Company has entered into a memorandum of understanding (the "MOU") with Humboldt Healthcare, LLC ("Humboldt Healthcare") to grant the Company an exclusive option (the "Option") to acquire a majority stake in real estate and intellectual property assets owned by Humboldt Healthcare that serve California's recreational marijuana sector (collectively, the "Assets").
LVRLF OPTI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EBR:OPTI / OPTION on message board site Silicon Investor.

NexOptic Technology Corp NexOptic Technology Corp NexOptic Technology Corp Option Strategies Option Strategies Option Strategies
Optical Networks and Components, DWDM and Tunable Lasers Optical Networks and Components, DWDM and Tunable Lasers Optical Networks and Components, DWDM and Tunable Lasers Options Investing: Trading the FTSE 100 and UK Stock Benchma Options Investing: Trading the FTSE 100 and UK Stock Benchma Options Investing: Trading the FTSE 100 and UK Stock Benchma
Gigoptix, Inc. Gigoptix, Inc. Gigoptix, Inc. Illumina (ILMN) Optics for Genomics Illumina (ILMN) Optics for Genomics Illumina (ILMN) Optics for Genomics
OPTI OPTI OPTI Broadband u0026 Fiber-Optic Companies to invest in. Broadband u0026 Fiber-Optic Companies to invest in. Broadband u0026 Fiber-Optic Companies to invest in.
Search Engines - options and opinions - Ask, Bing, Google, Search Engines - options and opinions - Ask, Bing, Google, Search Engines - options and opinions - Ask, Bing, Google, Binary Options Brokers - So Many To Choose, So Little Are Le Binary Options Brokers - So Many To Choose, So Little Are Le Binary Options Brokers - So Many To Choose, So Little Are Le